Titre : | Uso de neurolépticos atipicos en esquizofrénicos consumidores de cannabis |
Titre traduit : | (Usage de neuroleptique atypique chez des patients schizophrènes usagers de cannabis) ; (Atypical neuroleptics use in schizophrenics cannabis users) |
Auteurs : | L. A. NUNEZ DOMINGUEZ |
Type de document : | Périodique |
Année de publication : | 2001 |
Format : | 67-73 |
Note générale : |
Adicciones, 2001, 13, (1), 67-73
|
Langues: | Espagnol |
Discipline : | PSY (Psychopathologie / Psychopathology) |
Mots-clés : |
Thésaurus mots-clés NEUROLEPTIQUES ; CANNABIS ; COMORBIDITE ; SCHIZOPHRENIE ; PSYCHIATRIE ; COMPARAISON ; COHORTE ; EVALUATIONThésaurus géographique ESPAGNE |
Résumé : | The increasing research about comorbidity shows the growing importance of this topic in the current development of psychiatry. The majority of these papers discuss the importance of psychological treatment in these kind of patients, but there are a few number dealing with the pharmacological treatment. There are some references on the benefit of the atypical neuroleptics in the treatment of schizophrenic patients using cannabis. The aim of the present paper is trying to verify this hypothesis. Material and Methods: Three groups of patients with paranoid schizophrenia, two of them cannabis users, were included in this study. We made a one year follow-up after treatment with a classic (group ED) or an atypical (group AT) neuroleptic treatment Results: Group AT shows a lower frequency of cannabis use and a greater insight. Conclusions: Atypical neuroleptics could be useful in the management of schizophrenic patients with current cannabis use. (Review' s abstract) |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : |
Clinica San Francisco Javier, Ave. Baja Navarra, 52, 31002 Pamplona Espagne. Spain. |
Numéro Toxibase : | 1100901 |
Centre Emetteur : | 11 SEDAP |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil